Pamorelin Injection belongs to the class of 'Anti-Neoplastic Agents', primarily used to treat Prostate Cancer in men and early Breast Cancer in women.

It contains Triptorelin that belongs to the class of Gonadotropin-releasing Hormone (GnRH) agonists.

Triptorelin is a synthetic hormone that acts like the GnRH, produced by the Hypothalamus gland in the brain. It works by inhibiting the synthesis of the natural male hormone, testosterone in men, and oestrogen in women.

The lowering of testosterone hormone levels in men helps slow down the growth of Cancer cells in Prostate Cancer.

Pregnancy

Triptorelin must not be used during pregnancy since concurrent use of GnRH agonists is associated with a theoretical risk of abortion or foetal abnormality. Prior to treatment, potentially fertile women should be examined carefully to exclude pregnancy. Non-hormonal methods of contraception should be employed during therapy until menses resume.

Breast-feeding

Triptorelin is contraindicated during lactation period.

Pituitary Apoplexy

Rarely, treatment with GnRH agonists may reveal the presence of a previously unknown Gonadotrophic Cell Pituitary Adenoma. These patients may present with a pituitary apoplexy characterised by sudden headache, vomiting, visual impairment and Ophthalmoplegia.

Clinical studies performed in premenopausal women with hormone receptor positive early-stage Breast Cancer have been conducted with Triptorelin in order to suppress ovarian oestradiol secretion, the main source of oestrogens.

Based on the studies performed in healthy women and women with Endometriosis, the effect of Triptorelin in terms of oestradiol suppression is achieved as early as 3-4 weeks after the treatment initiation.

The toxicity of Triptorelin towards extragenital organs is low.